Company intelligence / Profile preview

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Salt Lake City, Utah, United States

Ownership: Private
Employees: ~500
Development stage: Other

Overview

The combined pipeline has more than 10 clinical and preclinical programs, with the most advanced in Phase 2 (e.g., REC-994 for cerebral cavernous malformation); oncology, rare diseases, and infectious diseases are key therapeutic areas. Ten clinical readouts expected before the end of 2025.

Modalities: Small molecule
Industry: Biotech

Partnerships

RocheGenentechSanofiBayerMerck KGaABristol Myers Squibb

Beyond the preview

Go deeper on Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc..

Explore the full profile